We’re honored to have received a variety of awards that represent the culmination of our team’s commitment to great science and to helping people with serious diseases. Here’s a little more about the awards and why Vertex was chosen:
The Prix Galien
The Galien Foundation is a non-profit group that “fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health.” Each year the foundation gives Prix Galien USA Awards in three categories – best pharmaceutical agent, best biotechnology product and best medical technology approved by the FDA in the past five years. The awards are given to “products or agents that improve the human condition.” This prestigious award is considered one of the industry’s top accolades and is also awarded in multiple countries around the world. Vertex received the Prix Galien USA award in 2012 for our work in hepatitis C, which began in 1993 with our scientists in our former Cambridge, MA headquarters. Vertex also received the 2013 French and German Prix Galien awards and the 2014 Dutch Prix Galien award for our work in cystic fibrosis, which began in 1998 at Vertex's San Diego, CA site.
PZ Innovation Award
The PZ Innovation Award is granted by the journal Pharmazeutische Zeitung (Pharmaceutical Newspaper) to recognize a new innovative pharmaceutical product in Germany each year; the winner is selected by an independent jury. Vertex received the PZ Innovation award in 2013 for our work in cystic fibrosis.
The Society for Medicines Research Award for Drug Discovery
The Society for Medicines Research (SMR) is a society based in the U.K. that brings together individuals and organizations engaged in research and development. The SMR hosts a symposium once a year with topics covering the latest advances in drug discovery and development and publishes a newsletter twice a year. The SMR believes that “outstanding contributions, achievements and inventions in the world of drug discovery and development should be recognized and celebrated.” To honor this, the SMR created the SMR Research Award for Drug Discovery to recognize individual scientists or teams of scientists for their contributions to the scientific community. Vertex received the SMR award in 2012 for our work in hepatitis C.
The Wall Street Journal’s 2012 Technology Innovation Awards
More than 500 submissions from 24 countries were considered in 2012 for The Wall Street Journal’s Technology Innovation Awards. After reviewing the entries, WSJ editors and reporters sent the top 172 to an independent team of judges from venture-capital firms, universities and companies to select the winners. The judges considered several criteria as they determined the winners and runners-up, including:
- Does the innovation break with conventional process in its field?
- Does it go beyond marginal improvement?
- Will it have a wide impact?
Winners were named across 18 categories, ranging from consumer electronics to transportation to medicine and biotech. This was the first time Vertex received this recognition from The Wall Street Journal, and we join the ranks of companies like Novartis, GlaxoSmithKline and Abbott Laboratories. The award reflects our team’s commitment for more than a decade to develop new medicines for CF – a project that began with our team of scientists at our San Diego research and development site.